Elfving, Pia http://orcid.org/0000-0002-9885-7242
Kariniemi, Simo http://orcid.org/0000-0001-8355-0531
Kautiainen, Hannu http://orcid.org/0000-0003-0786-0858
Rantalaiho, Vappu http://orcid.org/0000-0002-7470-3070
Virta, Lauri J. http://orcid.org/0000-0001-6909-3178
Puolakka, Kari http://orcid.org/0000-0003-1307-7421
Laine, Merja K. http://orcid.org/0000-0002-1848-1514
Funding for this research was provided by:
Pohjois-Savon Rahasto
the Research Committee of the Kuopio University Hospital Area
University of Eastern Finland
Article History
Received: 22 December 2023
Accepted: 21 February 2024
First Online: 2 April 2024
Declarations
:
: The authors declare that they have no conflict of interest in relation to this manuscript. The authors report the following financial activities outside the submitted work: H.K., L.J.V., K.P. and M.J.K. have no competing interests. P.E. has been on advisory board for Astra Zeneca and Otsuka, has received lecture fees from Abbvie and reimbursement of training and congress costs from Abbvie and received a research grant from the Finnish Cultural Foundation, North Savo Regional fund and the Research Committee of the Kuopio University Hospital Catchment Area for the State Research Funding. V.R. has received a lecture fee from Novartis and Viatris, reimbursement of training and congress costs from Abbvie and Pfizer and received BMS Research grant for Nord-Star trial, received a research grant from the Research Committee of the Tampere and Tavastia Catchment Area for the State Research Funding. S.K. has received reimbursement of training and congress costs from Abbvie, Medac and UCB and received a research grant from the Finnish Rheumatic Disease Research Foundation, the Maire Lisko Foundation and the Research Committee of the Kuopio University Hospital Catchment Area for the State Research Funding.